• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 杂交和接种疫苗免疫供体血清中针对两种保守冠状病毒抗原的交叉反应性分析。

Cross-Reactive Profile Against Two Conserved Coronavirus Antigens in Sera from SARS-CoV-2 Hybrid and Vaccinated Immune Donors.

机构信息

CCBJIC: China-Cuba Biotechnology Joint Innovation Center, Yongzhou, China.

CIGB: Vaccines & Pharmaceutics Division, Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba.

出版信息

Viral Immunol. 2023 Apr;36(3):222-228. doi: 10.1089/vim.2022.0186. Epub 2023 Feb 3.

DOI:10.1089/vim.2022.0186
PMID:36735580
Abstract

Since the beginning of the pandemic, the pre-existing immunity against SARS-CoV-2 has been postulated as one possible cause of asymptomatic infections. Later, various works reported that pre-existing immune response against the two structural conserved antigens: S2 subunit and the nucleocapsid protein, were associated to some level of asymptomatic profile in infected individuals. To explore the Ab background against these two antigens, in the context of vaccine-elicited and hybrid (natural infection plus vaccination induced) immunity of SARS-CoV-2, in this work, we tested sera from inactivated vaccine-immunized donors and from vaccinated and subsequent natural infected donors upon the Omicron variant wave in Guangdong province, China. Serum samples were collected from 27 COVID-19 convalescent, 25 SARS-CoV-2 vaccinated, and 10 negative donors. The IgG cross-reactivity response against these two antigens from another relevant human coronavirus (HCoV) was also evaluated. The findings indicate that IgG response against S2 and N protein was particularly higher in sera with hybrid immunity. The cross-reactive Abs were more significant against SARS-CoV-1, while a wide cross-reactivity was detected for N antigen for one human Alpha coronavirus HCoV-229E even in the negative control samples. The presence of cross-reactive Abs against the two conserved antigens N and S2, particularly in the context of hybrid immunity, could pave the way for future vaccines carrying these conserved regions.

摘要

自疫情开始以来,人们推测针对 SARS-CoV-2 的预先存在的免疫是无症状感染的一个可能原因。后来,各种研究报告表明,针对两种结构保守抗原(S2 亚单位和核衣壳蛋白)的预先存在的免疫反应与感染个体的某种程度的无症状特征相关。为了探索针对这两种抗原的 Ab 背景,在 SARS-CoV-2 疫苗引起的和混合(自然感染加疫苗诱导)免疫的背景下,在这项工作中,我们测试了来自灭活疫苗免疫供体的血清以及来自接种疫苗随后自然感染供体的血清,这些血清是在中国广东省的奥密克戎变异浪潮期间收集的。血清样本来自 27 例 COVID-19 恢复期患者、25 例 SARS-CoV-2 接种者和 10 例阴性供体。还评估了针对另一种相关人类冠状病毒(HCoV)的这两种抗原的 IgG 交叉反应性反应。研究结果表明,在具有混合免疫的血清中,针对 S2 和 N 蛋白的 IgG 反应特别高。针对 SARS-CoV-1 的交叉反应性 Abs 更为显著,而针对 N 抗原的广泛交叉反应性甚至在阴性对照样本中也检测到了一种人类 Alpha 冠状病毒 HCoV-229E。针对这两种保守抗原 N 和 S2 的交叉反应性 Abs 的存在,特别是在混合免疫的背景下,可能为携带这些保守区域的未来疫苗铺平道路。

相似文献

1
Cross-Reactive Profile Against Two Conserved Coronavirus Antigens in Sera from SARS-CoV-2 Hybrid and Vaccinated Immune Donors.SARS-CoV-2 杂交和接种疫苗免疫供体血清中针对两种保守冠状病毒抗原的交叉反应性分析。
Viral Immunol. 2023 Apr;36(3):222-228. doi: 10.1089/vim.2022.0186. Epub 2023 Feb 3.
2
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.交叉保护的 HCoV 免疫可减轻 SARS-CoV-2 感染期间的症状发生。
mBio. 2024 Feb 14;15(2):e0272223. doi: 10.1128/mbio.02722-23. Epub 2024 Jan 25.
3
Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.母亲在确诊 COVID-19 PCR、出现病毒症状且未暴露于病毒的情况下,母乳中针对 SARS-CoV-2、HCoV-OC43 和 HCoV-229E 的 S1 和 S2 亚单位的人乳抗体。
Int J Mol Sci. 2021 Feb 9;22(4):1749. doi: 10.3390/ijms22041749.
4
Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.检测血清交叉反应抗体和对 SARS-CoV-2 的记忆反应在大流行前和 COVID-19 后恢复期样本中。
J Infect Dis. 2021 Oct 28;224(8):1305-1315. doi: 10.1093/infdis/jiab333.
5
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.杂合免疫改变了 SARS-CoV-2 mRNA 疫苗诱导免疫的 Fc 效应子质量。
mBio. 2022 Oct 26;13(5):e0164722. doi: 10.1128/mbio.01647-22. Epub 2022 Aug 24.
6
Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.用于检测 COVID-19 恢复期血浆中 SARS-CoV-2 特异性 IgG 的多重冠状病毒抗原阵列的评估。
J Immunol Methods. 2021 Oct;497:113104. doi: 10.1016/j.jim.2021.113104. Epub 2021 Jul 22.
7
Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.2021 年 5 月波兰人群中对 SARS-CoV-2 具有免疫力的隐匿人群。
PLoS One. 2022 Feb 3;17(2):e0253638. doi: 10.1371/journal.pone.0253638. eCollection 2022.
8
The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.普遍冠状病毒免疫的前景:针对 SARS-CoV2 和常见人类冠状病毒的相互和非相互 T 细胞反应的特征。
Front Immunol. 2023 Oct 13;14:1212203. doi: 10.3389/fimmu.2023.1212203. eCollection 2023.
9
Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination.既往抗 HCoV-OC43 免疫影响 SARS-CoV-2 疫苗接种后体液免疫的持久性和交叉反应性。
Front Cell Infect Microbiol. 2022 Sep 2;12:978440. doi: 10.3389/fcimb.2022.978440. eCollection 2022.
10
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.

引用本文的文献

1
Obtaining HBV core protein VLPs carrying SARS-CoV-2 nucleocapsid conserved fragments as vaccine candidates.获得携带 SARS-CoV-2 核衣壳保守片段的 HBV 核心蛋白 VLPs 作为疫苗候选物。
Virol J. 2024 Nov 29;21(1):310. doi: 10.1186/s12985-024-02583-9.
2
A Nasal Vaccine Candidate, Containing Three Antigenic Regions from SARS-CoV-2, to Induce a Broader Response.一种包含来自严重急性呼吸综合征冠状病毒2(SARS-CoV-2)三个抗原区域的鼻用候选疫苗,可诱导更广泛的免疫反应。
Vaccines (Basel). 2024 May 28;12(6):588. doi: 10.3390/vaccines12060588.